Live Status Check

NCT05551793 Recruiting Status

Real-time enrollment status for this i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. clinical trial

Current Status

Recruiting

Auto-verified from ClinicalTrials.gov

Checked: March 2, 2026 at 8:47 AM UTC

NCT05551793 Status Summary

NCT NumberNCT05551793
Recruiting StatusRecruiting
ConditionI cannot determine the primary medical condition from the provided information. The study title mentions "Regeneron AA Multicenter (Dupilumab)" but "AA" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. The brief summary field appears to be incomplete (showing only a localhost URL). Without additional context about what condition dupilumab is being tested for in this specific trial, I cannot provide the patient-facing medical condition.
PhaseClinical Trial
Target Enrollment68 participants
Active Locations3 sites in the US
SponsorEmma Guttman
Last Updated on CT.govJuly 29, 2025 (Jul 29, 2025)

About NCT05551793 Enrollment Status

As of March 2, 2026: Clinical trial NCT05551793 is currently recruiting participants. This clinical trial study for i cannot determine the primary medical condition from the provided information. the study title mentions "regeneron aa multicenter (dupilumab)" but "aa" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. the brief summary field appears to be incomplete (showing only a localhost url). without additional context about what condition dupilumab is being tested for in this specific trial, i cannot provide the patient-facing medical condition. is actively seeking new participants at 3 locations across the United States. The study is sponsored by Emma Guttman. This status information is automatically verified from the official ClinicalTrials.gov registry.

Frequently Asked Questions About NCT05551793

Is NCT05551793 still recruiting?

Yes, NCT05551793 is actively recruiting participants as of March 2, 2026. You can check eligibility and apply through HelloStudys.

Where is NCT05551793 recruiting?

This trial is recruiting at 3 locations in the United States. View all available locations on the full study page.

How do I enroll in NCT05551793?

Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.

When was NCT05551793 status last updated?

The official ClinicalTrials.gov record for NCT05551793 was last updated Jul 29, 2025 (July 29, 2025). HelloStudys verifies this status automatically.

Browse More I cannot determine the primary medical condition from the provided information. The study title mentions "Regeneron AA Multicenter (Dupilumab)" but "AA" is too ambiguous, and the conditions field only lists drug names rather than medical conditions. The brief summary field appears to be incomplete (showing only a localhost URL). Without additional context about what condition dupilumab is being tested for in this specific trial, I cannot provide the patient-facing medical condition. Trials

Ready to Apply?

Check your eligibility for this clinical trial